Dutch leading St. Antonius Hospital to deploy two Vitestro blood drawing devices
• St. Antonius Hospital signs for two blood drawing devices that could help ease workload and provide a more consistent patient experience
• Expected commissioning in 2025, after Vitestro completes CE marking in late 2024
• St. Antonius Hospital is also one of the test sites in the A.D.O.P.T. clinical trial
Utrecht, The Netherlands, 7 December 2023 – The St. Antonius Hospital in Nieuwegein and Utrecht, the Netherlands, has finalized an agreement with Vitestro, a prominent medical robotics developer based in Utrecht, to introduce two state-of-the-art autonomous blood drawing devices into its daily operations. Following this agreement, the implementation of these cutting-edge devices is anticipated upon CE marking, which is expected to be obtained in late 2024.
Since 2017, Vitestro has dedicated its efforts to the development of an innovative blood-drawing device designed to ensure safe and accurate patient blood draws. The device combines AI-driven, ultrasound-guided 3D reconstruction, and submillimeter precision needle insertion, achieving a safe and more consistent blood collection.
The St. Antonius Hospital, a renowned institution in the Netherlands recognized for its specialized care in cardiovascular, pulmonary, and cancer diseases, is embarking on a significant progression in its collaborative efforts with Vitestro.
Annually, blood drawing occurs billions of times globally, serving a crucial role in diagnostic procedures. Despite its significance, clinical laboratories face substantial staff shortages. The automation of this common procedure is an important next step for clinical laboratories including those at St. Antonius Hospital, positively contributing to the quality of patient care and strengthening overall organizational sustainability.
From left to right: David Boss (Clinical Chemist, St. Antonius), Luuk Giesen (Chief Medical Officer, Vitestro), Aldrick Peterson (Business manager, St. Antonius), Brian Joseph (Commercial director, Vitestro), Wessel van Dijk (Head of Business development, Vitestro), Thijs van Holten (Clinical Chemist, St Antonius), Marc Koster (CFO and member of the Executive Board, St. Antonius), Chris Hackeng (Clinical Chemist, St. Antonius) and Dennis van Vogelpoel (Strategic purchasing manager, St. Antonius)
The St. Antonius Hospital played a proactive role in the device’s development since its inception in 2017. Subsequently, rigorous testing of the technology has been consistently and successfully conducted with patients at the St. Antonius Hospital; notably during the A.D.O.P.T. trial, a study launched earlier this year. Vitestro anticipates that the outcomes of the A.D.O.P.T. trial will lead to European CE marking by the end of 2024.
At St. Antonius Hospital, a strong emphasis on research and innovation fosters an environment conducive to conducting robust clinical studies, a testament to the institution's commitment to advancing healthcare.
The A.D.O.P.T. trial (Autonomous Blood Drawing Optimization and Performance Testing), stands as the largest trial to date globally with focus on autonomous blood drawing, involving over 10,000 patients. Alongside St. Antonius Hospital, Result Laboratorium at Albert Schweitzer Hospital, OLVG Lab, and Amsterdam UMC are collaborative partners in the study.
Marc Koster, member of the Board of Directors of St. Antonius Hospital, said:
"In Clinical Chemistry, several high-profile innovations are underway, such as blood transport with drones, the use of artificial intelligence for better diagnostics, and this automated blood drawing innovation. The hospital is an attractive partner for developers such as Vitestro."
"The vast majority of clinical chemistry laboratory processes have been automated for many years. This brings benefits, among other things, in the standardization of blood collection, improving quality. In addition, staff shortages in healthcare are hospital-wide, as is the case at our blood collection clinic. Staff drawing blood are under great work pressure and with these robots, we can reduce that pressure significantly. We expect that autonomous- and manual blood draws will continue to coexist."
"Meanwhile, patients are enthusiastic: almost all those surveyed at the blood draw clinic would like to use this robot for blood drawing."
In the near future, patients will have the option to autonomously undergo blood draws using the device, under the supervision of a trained healthcare professional. Vitestro's pioneering blood draw device will complement the conventional approach to manual blood draws.
Toon Overbeeke, CEO and co-founder at Vitestro, adds:
"Our device is undeniably the biggest innovation in blood collection in decades, and will go a long way to solve the sharply increasing shortage of healthcare personnel. Since 2018, we are closely working with the enthusiastic and driven team at the St. Antonius hospital. It is exciting to now take the next step in our collaboration."
In the upcoming quarters, several hospitals, laboratories and blood drawing departments are preparing for the deployment of Vitestro's devices through the Vitestro Academy.
Brian Joseph, Commercial Director and co-founder of Vitestro said:
“The first blood collection staff at St. Antonius Hospital have already participated in the Vitestro Academy, receiving comprehensive training in safe utilization and novel work processes of the innovation. Employees are eagerly anticipating the opportunity to improve patient care with this breakthrough device. Close cooperation within the healthcare ecosystem of the involved Dutch hospitals is crucial for a successful introduction of this game-changing technology."
About St. Antonius Ziekenhuis
- END OF PRESS RELEASE -
Five ambitious doctors and the Sisters of Charity laid the foundation for today's St. Antonius Hospital in 1910. A unique combination of people-orientation and drive for innovation has led to a medical organization with eight branches in the Central Netherlands. St. Antonius is (nationally) known for its expertise in heart, vascular, lung and cancer diseases. In addition, virtually all specialties are represented in our hospital. Working together to ensure quality of life for our patients and continually improving it is what our enthusiastic professionals work on every day. Training, research and innovation are essential for this and are therefore, in addition to patient care, part of our most important core tasks.
St. Antonius is a Santeon hospital. Santeon is a group of seven top clinical hospitals spread across the Netherlands that work together in a unique open way to demonstrably improve healthcare. Santeon professionals look in each other's kitchens and take the best results from each other. Together, we work on innovations in healthcare with our patients as our source of inspiration. For more information, visit www.antoniusziekenhuis.nl
ClinicalTrials.gov ID: NCT05878483
The purpose of this clinical trial with more than 10,000 patients is to evaluate the performance (efficacy) and safety of Vitestro's autonomous blood drawing device. Over Vitestro
Vitestro, an expert in medical robotics, has been developing a device for autonomous blood sampling from patients since 2017. The starting point for the innovation is to create a safe and consistent patient experience in addition to having a positive impact on solving the growing shortage of healthcare personnel.
The blood collection device combines ultrasound-guided 3D reconstruction based on AI with venipuncture. The procedure is fully automated, from applying the tourniquet to placing a bandage.
With a driven team of over 50 specialists, Vitestro is facing the toughest challenges to achieve the most advanced solutions in our era. Vitestro expects its autonomous blood collection technology to be available in the European market from the end of 2024 (www.vitestro.com). For more information contact:
Vitestro, Utrecht, Nederland
Toon Overbeeke, Chief Executive Officer
T: +31 30 200 4551
St. Antonius Ziekenhuis
Roeland Franck, communicatieadviseur
T: +31 6 158 82 054
LifeSpring Life Sciences Communication, Amsterdam
T: 31 6 538 16 427